Table 1.
Patient baseline characteristics
| Overall, N = 58 |
T-cell redirection, N = 28 |
Other, N = 30 |
P value | |
|---|---|---|---|---|
| Age at diagnosis, y, median (min-max) | 60 (35-77) | 59 (41-77) | 61 (35-77) | .9256 |
| Age at FST, y, median (min-max) | 67 (41-83) | 67 (47-81) | 67 (41-83) | .6022 |
| Months from diagnosis to FST, mo, median (min-max) | 82 (15-212) | 86 (46-212) | 69 (15-191) | .0415∗ |
| Gender, n (%) | ||||
| Male | 30 (52) | 14 (50) | 16 (53) | 1.0000 |
| Female | 28 (48) | 14 (50) | 14 (47) | |
| Myeloma subtype, n (%) | ||||
| IgG | 25 (43) | 14 (50) | 11 (37) | .5301 |
| IgA | 18 (31) | 7 (25) | 11 (37) | |
| IgM | 1 (2) | 0 (0) | 1 (3) | |
| IgD | 1 (2) | 1 (4) | 0 (0) | |
| Light chain | 13 (22) | 6 (21) | 7 (23) | |
| Cytogenetics, n (%) | ||||
| High risk | 45 (78) | 19 (68) | 26 (87) | .1187 |
| Standard risk | 13 (22) | 9 (32) | 4 (13) | |
| Number of prior lines of therapy, median (min-max) | 6 (3-17) | 7 (3-16) | 6 (3-17) | .6836 |
| Number of prior autologous stem cell transplants, n (%) | ||||
| 0 | 10 (17) | 5 (18) | 5 (17) | 1.0000† |
| 1 | 34 (59) | 16 (57) | 18 (60) | |
| 2 | 14 (24) | 7 (25) | 7 (23) | |
| Refractoriness, n (%) | ||||
| No | 0 (0) | 0 (0) | 0 (0) | 1.0000 |
| Yes | 58 (100) | 28 (100) | 30 (100) | |
| Triple-class refractory | 51 (88) | 25 (89) | 26 (87) | .7617 |
| Penta-drug refractory | 25 (43) | 13 (46) | 12 (40) | .6243 |
| Thalidomide | 6 (10) | 3 (11) | 3 (10) | 1.0000 |
| Lenalidomide | 44 (76) | 19 (68) | 25 (83) | .2244 |
| Pomalidomide | 49 (84) | 23 (82) | 26 (87) | .7260 |
| Bortezomib | 37 (64) | 19 (68) | 18 (60) | .5925 |
| Ixazomib | 6 (10) | 3 (11) | 3 (10) | 1.0000 |
| Carfilzomib | 48 (83) | 23 (82) | 25 (83) | 1.0000 |
| Elotuzumab | 19 (33) | 6 (21) | 13 (43) | .0973 |
| CD38 | 56 (97) | 28 (100) | 28 (93) | .4918 |
| Selinexor | 12 (21) | 6 (21) | 6 (20) | 1.0000 |
| Alkylator | 32 (55) | 15 (54) | 17 (57) | 1.0000 |
| BiAb target on trial, n (%) | ||||
| BCMAxCD3 | 9 (16) | 5 (18) | 4 (13) | .7260 |
| GPRC5DxCD3 | 49 (84) | 23 (82) | 26 (87) | |
| Extramedullary disease before the trial, n (%) | 19 (33) | 9 (32) | 10 (33) | 1.0000 |
| Extramedullary disease at relapse from BiAb trial, n (%) | 23 (40) | 11 (39) | 12 (40) | 1.0000 |
| Extramedullary disease after first salvage, n (%) | 22 (38) | 8 (29) | 14 (47) | .1844 |
| Eastern Cooperative Oncology Group performance status at FST, n (%) | ||||
| 0 | 24 (41) | 13 (46) | 11 (37) | .3121 |
| 1 | 30 (52) | 15 (54) | 15 (50) | |
| 2 | 3 (5) | 0 (0) | 3 (10) | |
| 3 | 1 (2) | 0 (0) | 1 (33) | |
| Radiation therapy at FST, n (%) | 12 (21) | 5 (18) | 7 (23) | .6069 |
| Prior BCMA ADC, n (%) | 3 (5) | 1 (4) | 3 (7) | 1.0000 |
| Prior CAR T-cell therapy, n (%) | 3 (5) | 0 (0) | 3 (10) | .2377 |
| Hemoglobin at FST, median (min-max) | 10.3 (7.1-14.4) | 11.2 (7.6-14.4) | 9.9 (7.1-12.2) | .0075∗ |
| Platelet count at FST, median (min-max) | 168 (26-749) | 191 (59-456) | 142.5 (26-749) | .0137∗ |
| Absolute neutrophil count at FST, median (min-max) | 3 (0.6-7.4) | 2.8 (0.7-7.4) | 3.1 (0.6-0.1) | .9938 |
| Creatinine level at FST, median (min-max) | 1 (0.4-2.1) | 1.0 (0.5-2.1) | 1.0 (0.4-1.7) | .8586 |
| Calcium level at FST, median (min-max) | 9.1 (7.5-14.8) | 9.2 (8.1-10.5) | 9.1 (7.5-14.8) | .7446 |
IgG, immunoglobulin G.
∗
P value < .05.
†
Among patients that underwent autologous stem cell transplant.